A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects

Stopped early · Phase 1

Conditions studied: HIV, Tuberculosis

In brief

The purpose of this study is to study the safety, tolerability and pharmacokinetics of rifabutin dosing with lopinavir/ritonavir tablets in healthy volunteers.

Key facts

Study ID

NCT00743470

Run by

Abbott

People needed

15

Starts

2008-08-01

Last updated by the study team

2010-11-02

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Adult Male or Female 18-55 yrs.
• Subject has provided written consent.
• Subject is in general good health.
• If female, subject is postmenopausal.
• If female, subject is not pregnant and is not breast-feeding.
• Subject must use birth control methods or be surgically sterile.

You may not qualify if…

• Subject is HAV-IgM, HBsAg or HIV Ab positive.
• Positive screen for drugs of abuse, alcohol, or smoking.
• Cannot be on any medication, including over the counter drugs.
• Cannot have previous history of alcohol or drug abuse.
• Cannot have history of any major diseases or disorders.

Where it is running

• Site Reference ID/Investigator# 11441 — Waukegan, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.